A research team led by Professor Won Jong Kim (CHEM) has developed a lymph-directed self-immolative nitric oxide prodrug that is readily conjugated to the protein albumin in order to remove cancer cells in lymph nodes. Prodrugs are drugs that need to be metabolized in the body to be therapeutic.
Since nitric oxide (NO) can trigger various biological reactions in the body, studies have been conducted to use it for anti-cancer therapy. However, conventional NO drugs are difficult to use for medical purposes since they spontaneously release NO gas due to their innate structural instability.
The drug developed by this team is unique in that it selectively reacts with strong reductants inside the body to release NO. In this study, using albumin, which enables the drug’s rapid drainage into the lymph nodes, the prodrug is able to eliminate cancer cells located in the tumor-draining lymph nodes.
In a metastasis mouse model, the mice treated with the drug had about 30 times less weight of metastatic cancer cells in the lymph node than those not treated. Also, 85% of the mice treated with the drug survived, whereas only 14% of the untreated survived.
Unlike conventional NO prodrugs, the newly developed prodrug does not spontaneously decompose when it comes in contact with water, rendering it easy to store or transport. Side effects are also significantly lower compared to performing lymph node removal surgeries. The drug also has high potential for commercialization since 3-morpholinosydnonimine hydrochloride (SIN-1)—a component of the drug–has already been used clinically and albumin is also a protein present in the body.
“The self-immolative nitric oxide prodrug can minimize the side effects of nitric oxide and maximize its therapeutic effects,” explained Prof. Kim. He noted, “It will be applicable to the prevention and treatment of cancer, autoimmune diseases, intractable neurological diseases, and infectious diseases in the future.”
Published on Jan. 5 in Advanced Science, the study was conducted as an academia-industry collaborative project with OmniaMed Co., Ltd. and supported by the Basic Research Program and Creative Materials Discovery Program of the National Research Foundation of Korea.